T1	Participants 177 229	patients with unresectable pancreatic adenocarcinoma
T2	Participants 243 269	Advanced pancreatic cancer
T3	Participants 686 781	Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas
T4	Participants 1063 1088	25 patients were enrolled
T5	Participants 1090 1123	Nineteen patients were randomised
